AUS
NZ
UK
CA
USA
IND
Healt
Mesoblast (ASX:MSB) Gains Momentum with FDA Approval for Ryoncil Therapy
December 19, 2024 06:16 PM AEDT| By Team Kalkine MediaHighlights,FDA approval boosts Mesoblast (MSB) with new therapy Ryoncil.,Ryoncil marks the first approved therapy for SR-aGvHD in the US.,Mesoblast secures strong market positioning for innovative cell therapy.,Biotech company Mesoblast (ASX:MSB) wit...
Mesoblast's (ASX:MSB) Ryoncil Secures Historic FDA Approval for SR-aGvHD
December 19, 2024 03:12 PM AEDT| By Team Kalkine MediaHighlights,Ryoncil,becomes the first FDA-approved mesenchymal stromal cell therapy for SR-,aGvHD,.,Mesoblast (,ASX:MSB,) expands treatment options for children with severe graft-versus-host disease,.,The company to debut on the Nasdaq Biotechnology I...
Breakthrough: Mesoblast (ASX:MSB) Gains FDA Approval for First MSC Therapy in the US
December 19, 2024 01:54 PM AEDT| By Team Kalkine MediaHighlights,Mesoblast (MSB) secures FDA approval for RYONCIL®,.,RYONCIL,becomes,the first mesenchymal stromal cell therapy approved in the US,.,Significant impact,anticipated,for pediatric graft-versus-host disease treatment,.,Mesoblast (ASX:MSB) has...
Austco Healthcare Limited (ASX:AHC): Examining Performance Metrics Amid Market Dynamics
December 19, 2024 12:25 PM AEDT| By Team Kalkine MediaHighlights:,Austco Healthcare Limited (,ASX:AHC,) has a price-to-earnings (P/E) ratio of 13.9x, significantly lower than the broader Australian market average.,The company has shown strong earnings growth, including a 198% gain in the last year and a...
LTR Pharma Partners with Men’s Health Downunder for Erectile Dysfunction Nasal Spray Rollout
December 19, 2024 12:12 PM AEDT| By Team Kalkine MediaHighlights,LTR Pharma partners with MHDU to introduce SPONTAN, a nasal spray for erectile dysfunction.,Collaboration provides access to MHDU’s extensive referral network, including GPs, urologists, and sexual health clinics.,Real-world patient data c...
Mesoblast Shares Surge 33% as FDA Approves Groundbreaking RYONCIL® Therapy
December 19, 2024 12:07 PM AEDT| By Team Kalkine MediaHighlights,FDA approves Mesoblast’s RYONCIL® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy in the U.S.,RYONCIL becomes the only approved treatment for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.,Meso...
Orthocell (ASX:OCC) Advances Nerve Repair Innovation with FDA Submission for Remplir™
December 19, 2024 11:21 AM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC),submits,FDA application for,Remplir,™, targeting the expansive US nerve repair market,.,Successful study positions,Remplir,™ as a safe and effective solution for peripheral nerve repair,.,Company prepares for US launch, sup...
Cochlear (ASX:COH) Shares: Why Healthcare Stocks are Attracting Attention
December 18, 2024 01:27 PM AEDT| By Team Kalkine MediaHighlights,Cochlear (COH) focuses on advanced hearing solutions with stable revenue growth,.,The healthcare sector,demonstrates,resilience in challenging economic conditions,.,Cochlear,maintains,steady dividends while expanding its global market pres...
Percheron Therapeutics (ASX:PER) Shares Phase IIb Duchenne Results
December 18, 2024 12:47 PM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics (PER) announces Phase IIb trial results of,avicursen,in DMD,.,The trial did not meet its primary efficacy endpoint but confirmed safety and tolerability,.,Further data expected in early 2025 to guide the drug's devel...
Innovative Psilocybin Therapy Shows Promise in Phase 2a IBS Trial
December 18, 2024 12:39 PM AEDT| By Team Kalkine MediaHighlights,Promising interim results for TRP-8802 in IBS trial at Massachusetts General Hospital,.,TRP-8803 highlighted as a potential treatment with advanced delivery benefits,.,Clinical program expands focus to address broader mental health and pai...
Clarity Pharmaceuticals (ASX:CU6) Launches New Cancer Radiopharmaceutical
December 18, 2024 11:30 AM AEDT| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (CU6) advances a new radiopharmaceutical, SAR-,bisFAP,The product targets multiple cancers with diagnostic and treatment potential,SAR-,bisFAP,demonstrated improved retention and uptake in preclinical trials,Clarity...
Ramsay Health Care (ASX:RHC) Faces Five-Year Decline in Share Price and Earnings
December 18, 2024 11:12 AM AEDT| By Team Kalkine MediaHighlights,Ramsay Health Care (RHC) faces long-term stock decline,.,Earnings per share (EPS) fell annually over the last five years,.,Total shareholder returns were supported by dividends,.,Ramsay Health Care (ASX:RHC), a leading player in the health...
Actinogen Medical (ASX:ACW) Faces Challenges Despite Strong Revenue Growth
December 17, 2024 06:54 PM AEDT| By Team Kalkine MediaHighlights,Actinogen Medical (ACW) shares experienced significant volatility over the past three years.,Revenue growth has been substantial but share price performance remains under pressure.,Insider buying in the last three months signals confidence...
Prescient Therapeutics Appoints Global Pharmaceutical Leader as New CEO
December 17, 2024 01:42 PM AEDT| By Team Kalkine MediaHighlights,Prescient Therapeutics (PTX) names James McDonnell as its new CEO,McDonnell has extensive experience in global oncology and pharmaceutical sectors,The appointment is effective from January 20, 2025,Prescient Therapeutics (ASX:PTX), a clini...
Immutep Reports Positive Safety Data for Flagship Drug IMP761, Shares Slip 3%
December 17, 2024 12:26 PM AEDT| By Team Kalkine MediaHighlights,Immutep tested IMP761, a LAG-3 agonist, in a conceptual safety study involving 49 healthy participants.,No adverse effects were reported, confirming the safety of the world’s first LAG-3 agonist antibody in its early testing phase.,The stu...
Race Oncology (ASX:RAC) Advances Cancer Research with R&D Rebate
December 17, 2024 12:01 PM AEDT| By Team Kalkine MediaHighlights,Race Oncology secures over A$5 million R&D rebate to advance lead drug,bisantrene,Funding boosts R&D for both domestic and international projects,Key focus on addressing unmet needs in oncology treatments,Race Oncology (ASX:RAC) has receiv...
Anteris Technologies Now Trading on Nasdaq and ASX Following Re-domiciliation
December 17, 2024 11:36 AM AEDT| By Team Kalkine MediaHighlights,Anteris,completes re-domiciliation to the US and begins trading on Nasdaq,.,Shares of,Anteris,Technologies listed under (AVR) on the ASX and Nasdaq,.,IPO funds will accelerate heart valve product development and clinical trials,.,Anteris T...
Control Bionics Targets Strong US Revenue Growth and Expands Market Reach
December 17, 2024 10:58 AM AEDT| By Team Kalkine MediaHighlights,Control Bionics (CBL) expects strong revenue growth for the US market in FY25,.,Operational initiatives and cost reductions drive improved efficiency,.,Growing demand for Drove module strengthens market presence,.,Control Bionics (ASX:CBL)...
ECS Botanics Reports Record Cannabis Yields with Enhanced Enclosures
December 16, 2024 03:45 PM AEDT| By Team Kalkine MediaHighlights,ECS Botanics (ECS) achieves a 50% increase in cannabis flower yields through innovative enclosure designs.,Enhanced enclosures deliver improved flower quality and higher-grade cannabis buds.,New infrastructure positions the company for inc...
Orthocell (ASX:OCC) Marks Key Milestone with First Sales of Remplir™ in Singapore
December 16, 2024 01:44 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC) achieves initial sales of,Remplir,™ in Singapore,.,Expansion into Singapore positions the product in the ASEAN region's nerve repair market,.,Regulatory filings for US FDA clearance set to accelerate growth globally,.,Ortho...
Advertise your brand on Kalkine Media